Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.
about
In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor?Is lipid signaling through cannabinoid 2 receptors part of a protective system?In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain modelsThe CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onsetThe cannabinoid CB2 receptor as a target for inflammation-dependent neurodegenerationSpecies-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomersMicroglial Cells as a Link between Cannabinoids and the Immune Hypothesis of Psychiatric DisordersTherapeutic potential of monoacylglycerol lipase inhibitorsThe CB2 receptor and its role as a regulator of inflammationTargeting cannabinoid agonists for inflammatory and neuropathic painBrain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjectsEffects of a selective cannabinoid CB2 agonist and antagonist on intravenous nicotine self administration and reinstatement of nicotine seekingFunctional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depressionCB2 Cannabinoid Receptor Knockout in Mice Impairs Contextual Long-Term Memory and Enhances Spatial Working Memory.The endocannabinoid system in anxiety, fear memory and habituation.Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects.Brain CB₂ Receptors: Implications for Neuropsychiatric Disorders.Intracranial self-stimulation to evaluate abuse potential of drugs.Estrogen rapidly enhances incisional pain of ovariectomized rats primarily through the G protein-coupled estrogen receptor.Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedsideCB2: a cannabinoid receptor with an identity crisisCelastrol attenuates inflammatory and neuropathic pain mediated by cannabinoid receptor type 2.Brain cannabinoid CB₂ receptors modulate cocaine's actions in miceModulation of pain transmission by G-protein-coupled receptors.Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawalThe CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects.Peripheral and central sites of action for the non-selective cannabinoid agonist WIN 55,212-2 in a rat model of post-operative painChronic blockade of cannabinoid CB2 receptors induces anxiolytic-like actions associated with alterations in GABA(A) receptors.Identification of the major prostaglandin glycerol ester hydrolase in human cancer cells.Arthritis and pain. Future targets to control osteoarthritis painRole of the endogenous cannabinoid system in nicotine addiction: novel insights.2,3-Dihydro-1-benzofuran derivatives as a series of potent selective cannabinoid receptor 2 agonists: design, synthesis, and binding mode prediction through ligand-steered modeling.CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.Separate and combined effects of the GABA reuptake inhibitor tiagabine and Δ9-THC in humans discriminating Δ9-THC.The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.The endocannabinoid system: current pharmacological research and therapeutic possibilities.Therapeutic modulation of cannabinoid lipid signaling: metabolic profiling of a novel antinociceptive cannabinoid-2 receptor agonistLatest advances in novel cannabinoid CB(2) ligands for drug abuse and their therapeutic potential.The peripheral cannabinoid receptor knockout mice: an update.New anti-inflammatory agents to reduce atherosclerosis.
P2860
Q24564956-6EDDEF5B-4E07-4189-B007-0580129AAA68Q24633122-E7C6F21F-DC16-40C4-AB37-161CD47ADAF6Q24643672-A2E621A6-3E47-43BD-9064-53E18C2161BEQ24650098-3B647A5C-A07E-4B61-A86E-5532D4EE01ADQ24651712-D85F66FB-B63A-4439-8CAB-5F29D319BC8EQ24673335-59DA9D9E-DC14-4462-BA3D-50168CE8C8A5Q26767489-8E743DB8-116B-46EA-AE30-081CC9092689Q26991513-155BBAD1-9F1E-4C7D-940C-D4A2F5FFCC74Q28066700-D17F1F0B-ECBC-4982-A9B1-90E39A6C9C32Q28307619-CA62E528-3C85-47C1-BD6C-B04C1124B212Q28472191-A042A2EB-5AC9-4779-94F8-F14246FFAD2EQ28480387-764C1844-498B-4176-8E35-10C5B83632D5Q28566269-C5B586F4-5425-4D67-BB58-0BCD2993E9B2Q30392902-6BB6CFB0-4DD1-4EC5-BAE3-7B2EF1150DBEQ30471032-8B4628B8-E3FA-44CF-B038-D240CE4AA9D1Q30473707-32B428B8-E5A2-4172-9B59-6ABA07DF5A5AQ33664105-C6822FA0-2B83-4F75-A049-42F8ACF7FF4BQ33845750-6CAB3A03-33C0-4704-98C3-573826485440Q33907799-AFC79052-5606-47A0-B102-29F5A2D0A84BQ34019573-6609784D-7605-48FA-A2EE-D3CCB51F0EECQ34098185-50713107-12C4-4402-AB9F-0B4E5D4C3E97Q34158418-84F41FBA-9264-4D79-A206-372686987825Q34203193-4FEF5DF7-C718-4896-9A2C-AC3DA2B725D1Q34247711-AB773FAF-4F5D-4282-95CA-DFA005867CC8Q34403197-BD4B49B4-9028-42DD-8F0E-85E68F389B78Q34496064-AE2D0BBB-172D-4580-94AF-C227FFB5E36FQ34606612-66B0475E-B2E8-4AEA-93A2-AC2467B76C52Q34631608-11D3433E-8C70-4BDD-84B2-8B33F1EB060BQ34634096-F263F706-2904-4ACB-B3D3-9CC037502FDCQ34636446-EA6BAE0B-CBB4-42B6-A47C-58648D29C1E0Q35216481-56A4528E-2565-41BA-963B-B378CEBCD4AEQ35685828-85EBC5FB-CD63-4CF5-8B88-D74909AB7F76Q35745959-BAD10538-E0C6-4BE9-8F64-41EC98AB2B73Q35840095-1465357B-3BF4-46FA-983F-9A87D4519CEEQ36341688-D149831F-3167-4CDF-8E50-6D99A18624D2Q36381416-4CC61A4C-EC76-4F94-8E8B-C452D92CA3C3Q36385052-DAE8447B-D8C8-48CF-B94B-7BDF661235E3Q36408464-3D6A4D87-36CC-4260-A102-5044EDD4AF9AQ36416347-A8C83BAC-BB77-47FD-83F6-736A811F9794Q36576558-6284E988-825F-4422-A7BF-76C814496072
P2860
Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Pharmacological and pharmacoki ...... anxiety, ataxia and catalepsy.
@ast
Pharmacological and pharmacoki ...... anxiety, ataxia and catalepsy.
@en
Pharmacological and pharmacoki ...... anxiety, ataxia and catalepsy.
@nl
type
label
Pharmacological and pharmacoki ...... anxiety, ataxia and catalepsy.
@ast
Pharmacological and pharmacoki ...... anxiety, ataxia and catalepsy.
@en
Pharmacological and pharmacoki ...... anxiety, ataxia and catalepsy.
@nl
prefLabel
Pharmacological and pharmacoki ...... anxiety, ataxia and catalepsy.
@ast
Pharmacological and pharmacoki ...... anxiety, ataxia and catalepsy.
@en
Pharmacological and pharmacoki ...... anxiety, ataxia and catalepsy.
@nl
P2093
P921
P1433
P1476
Pharmacological and pharmacoki ...... anxiety, ataxia and catalepsy.
@en
P2093
David A Elsemore
Garth T Whiteside
James E Harrison
Jamie M Boulet
Kenneth J Valenzano
Laykea Tafesse
Leyana Rabadi
Lilly Mark
Mathew Toth
P304
P356
10.1016/J.NEUROPHARM.2004.12.008
P50
P577
2005-04-01T00:00:00Z